Top Page
VSee Health
(NASDAQ:VSEE)
VSee Health (VSEE) vs. SPDR S&P 500 ETF (SPY)
VSee Health Business Overview & Revenue Model
VSee Health Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.55M | 10.42M | 5.77M | 6.38M | 7.34M | 6.80M |
| Gross Profit | 7.95M | 7.18M | 3.83M | 4.84M | 5.92M | 5.46M |
| EBITDA | -5.55M | -3.36M | -1.79M | 0.00 | 0.00 | 0.00 |
| Net Income | -12.48M | -57.70M | -3.76M | -836.21K | 475.90K | 258.88K |
Balance Sheet | ||||||
| Total Assets | 18.71M | 19.99M | 805.79K | 2.61M | 117.94M | 2.73M |
| Cash, Cash Equivalents and Short-Term Investments | 472.76K | 326.12K | 118.73K | 230.66K | 760.01K | 775.24K |
| Total Debt | 3.46M | 9.55M | 543.00K | 517.13K | 0.00 | 133.08K |
| Total Liabilities | 24.28M | 20.01M | 5.11M | 2.61M | 4.55M | 2.11M |
| Stockholders Equity | -5.58M | -18.49K | -3.97M | 360.72K | 113.39M | 614.49K |
Cash Flow | ||||||
| Free Cash Flow | -4.52M | -5.84M | -636.93K | -1.45M | -600.11K | 789.12K |
| Operating Cash Flow | -4.49M | -5.79M | -632.60K | -1.45M | -600.11K | 789.12K |
| Investing Cash Flow | -27.54K | -26.14K | -4.33K | 110.12M | -116.73M | 0.00 |
| Financing Cash Flow | 2.67M | 6.02M | 525.00K | -109.32M | 118.09M | -83.67K |
VSee Health Technical Analysis
VSee Health Risk Analysis
VSee Health Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $74.49M | -0.63 | -38.35% | ― | 4.33% | 50.50% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $967.23M | -4.26 | -15.42% | ― | -2.37% | 77.85% | |
43 Neutral | $12.19M | -2.45 | -8.96% | ― | -24.64% | 92.19% | |
38 Underperform | $13.28M | -0.47 | ― | ― | 187.24% | 82.90% |
VSee Health Corporate Events
On December 30, 2025, VSee Health, Inc. held its annual meeting of stockholders for the fiscal year ended December 31, 2025, with 35.74% of voting power represented, enough to constitute a quorum. Stockholders elected Dr. Milton Chen and Dr. Imoigele Aisiku as Class I directors to serve until the 2028 annual meeting, ratified WWC, P.C. as independent auditor for the 2025 fiscal year, approved the 2025 Equity Incentive Plan, and authorized the potential adjournment of the meeting, though this adjournment proposal was ultimately withdrawn because all other proposals passed. The outcomes solidify the company’s governance structure, maintain continuity in its auditing relationship, and provide a refreshed equity compensation framework, which together support management’s ability to retain talent and pursue its strategic objectives on a stable shareholder-approved footing.
The most recent analyst rating on (VSEE) stock is a Hold with a $0.37 price target. To see the full list of analyst forecasts on VSee Health stock, see the VSEE Stock Forecast page.
VSee Health, Inc. amended its bylaws on December 17, 2025, to lower the quorum requirement for stockholder meetings to one-third of the voting power of outstanding shares entitled to vote, whether present in person or by proxy. The reduced quorum threshold was applied retroactively to the company’s 2025 Annual Meeting of Stockholders, scheduled to be held via live webcast on December 30, 2025, a move that could make it easier for the company to conduct official business and secure stockholder approvals with a smaller proportion of shareholders participating.
The most recent analyst rating on (VSEE) stock is a Hold with a $0.54 price target. To see the full list of analyst forecasts on VSee Health stock, see the VSEE Stock Forecast page.
On December 12, 2025, VSee Health announced the postponement of its 2025 Annual Meeting of Stockholders due to an anticipated lack of quorum. Originally scheduled for December 15, the meeting will now take place on December 30, 2025, via live webcast. The company emphasized that no changes have been made to the proposals to be voted on and encouraged stockholders to read the definitive proxy statement and vote by December 29, 2025.
The most recent analyst rating on (VSEE) stock is a Hold with a $0.54 price target. To see the full list of analyst forecasts on VSee Health stock, see the VSEE Stock Forecast page.
On December 4, 2025, VSee Health, Inc. filed a Certificate of Designation for its Series B Convertible Preferred Stock, effective December 5, 2025. This move outlines the preferences, rights, and limitations of the Series B stock, which ranks senior to common stock and junior securities, on parity with Series A preferred stock, and junior to any future senior securities. The Series B stock is convertible to common stock under certain conditions and carries specific dividend rights, impacting the company’s capital structure and potentially influencing shareholder value.
The most recent analyst rating on (VSEE) stock is a Hold with a $0.54 price target. To see the full list of analyst forecasts on VSee Health stock, see the VSEE Stock Forecast page.
On September 2, 2025, VSee Health received a notification from Nasdaq indicating non-compliance with the equity rule due to a stockholders’ deficit. Following an appeal and a hearing on September 9, 2025, the Nasdaq Hearings Panel granted VSee Health an exception to complete its compliance plan. The company has since undertaken various transactions, including warrant exercises and stock conversions, to meet the equity rule requirements. A pro forma balance sheet, assuming these transactions closed by December 31, 2025, shows compliance with the equity rule, with total stockholders’ equity of $13.2 million.
The most recent analyst rating on (VSEE) stock is a Sell with a $0.51 price target. To see the full list of analyst forecasts on VSee Health stock, see the VSEE Stock Forecast page.
On November 25, 2025, VSee Health, Inc. entered into a securities purchase agreement with an institutional investor to sell approximately 9.8 million shares of common stock and accompanying warrants in a private placement for gross proceeds of about $6 million. The proceeds are intended for working capital and general corporate purposes, with the closing expected around December 1, 2025, subject to customary conditions. The agreement includes provisions for stockholder approval and restrictions on further stock issuance, impacting the company’s financial strategy and shareholder relations.
The most recent analyst rating on (VSEE) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on VSee Health stock, see the VSEE Stock Forecast page.
On November 17, 2025, VSee Health, Inc. announced the issuance of a Convertible Promissory Note and plans to issue shares of Common Stock upon conversion of the Note. This move is made under the exemption from registration provided by the Securities Act of 1933 and Regulation D. The agreement, dated October 29, 2025, marks a significant financial maneuver for VSee Health, potentially impacting its market operations and investor relations.
The most recent analyst rating on (VSEE) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on VSee Health stock, see the VSEE Stock Forecast page.
On November 13, 2025, VSee Health, Inc. entered into an Exchange Agreement and a Directed Stock Purchase Agreement (DSPA) with an investor. The company plans to issue shares of its Common Stock under exemptions from the registration requirements of the Securities Act, specifically under Section 3(a)(9) and/or Regulation D for the Exchange Agreement, and Section 4(a)(2) and/or Regulation D for the DSPA. This move involves accredited investors as defined under Regulation D, potentially impacting VSee Health’s financial strategy and investor relations.
The most recent analyst rating on (VSEE) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on VSee Health stock, see the VSEE Stock Forecast page.